Kevin Punie
@kevinpunie
Followers
3K
Following
11K
Media
739
Statuses
5K
Medonc @ZAS_Ziekenhuis @AntwerpOncology 🇹🇩Knight to improve outcome of patients w/ breast cancer 🧬 #TNBC #BCY #HereditaryCancer @myBSMO @EORTC_BCG @ESMO
Leuven, België
Joined December 2018
RT @GuiNaderMarta: Honored to join the @myESMO Young Oncologists Committee! . Grateful for the opportunity to contribute and help support t….
0
4
0
RT @Lucarecco: New @myESMO germline testing recommendations in BC. MGPT should include 7 genes with proven impact on BC-related mortality:….
0
17
0
RT @OncoAlert: Dear Colleagues at #ASCO25.You are warmly invited to watch the Top Trials of the Year, presented by some of the world’s lead….
0
10
0
RT @OncoAlert: Dear Colleagues at #ASCO25 . An honor to present @angela_toss Presenting on Association between type of BRCA1/2 pathogenic/l….
0
18
0
RT @StephenVLiu: This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infus….
0
489
0
RT @OncoAlert: An honor to present our @OncoAlert #BreastCancer Faculty @ErikaHamilton9 🇺🇸Who just presented the Results of VERITAC-2 at #A….
0
23
0
RT @OncoAlert: An honor to Present our @OncoAlert 🚨#BreastCancer Faculty @stolaney1 🇺🇸 from @DanaFarber who just presented ASCENT-04 at #A….
0
19
0
RT @OncoAlert: The #OncoAlert5k at #ASCO25 is Tomorrow Saturday May 31, 2025 at 7 AM. Meeting in the FRONT of the McCormick by the LARGE AS….
0
8
0
RT @OncoAlert: The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer . These are some of our picks of TOP abstracts we look forward to be….
0
24
0
RT @PTarantinoMD: One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL….
0
133
0
RT @OncoAlert: The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer.These are some of our picks of TOP abstracts we look forward to be pr….
0
55
0
RT @OncoAlert: NEWS FROM INDUSTRY: Source Business Wire.Update ASCENT-03. The Phase 3 ASCENT-03 trial sees sacituzumab govitecan-hziy impro….
0
17
0
RT @SuyogCancer: Top 10 Breast Cancer Trials to Watch at #ASCO25.Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC!.1️⃣ DESTINY-Breast09 –….
0
97
0
RT @PTarantinoMD: Sara Tolaney from @DFCI_BreastOnc reviews a rainbow of novel treatment options becoming available for HR+/HER2- mBC over….
0
36
0
RT @aftimosp: Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel….
0
7
0
RT @BRicciutiMD: Hi everyone - my previous account @BiagioRicciutMD was compromised and is no longer under my control. This is my new offi….
0
7
0
RT @myESMO: 📣ESMO Living Guidelines on Metastatic Breast Cancer: .👉Just updated with the latest recommendations and algorithms in an intera….
0
25
0
RT @OncoAlert: NEWS FROM INDUSTRY.Source Gilead. Gilead announces positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial, showing th….
0
23
0
RT @OncoAlert: NEWS FROM INDUSTRY.Source AstraZeneca. The Phase III DESTINY-Breast09 trial marks a significant adv….
0
37
0
RT @GileadSciences: We’re sharing topline results from our Phase 3 ASCENT-04 study for people living with metastatic triple-negative breast….
0
18
0